Loading stock data…
CTNM
$12.96-0.19 (-1.44%)
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$12.96
Potential Upside
5%
Whystock Fair Value$13.61
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-7...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$483.88M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.39
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-26.13%
Volume
Today's trading volume
236,461
Recent News
We Think Contineum Therapeutics (NASDAQ:CTNM) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. By way of example...
Contineum Therapeutics Highlights PIPE-791 IPF Trial, J&J-Backed PIPE-307 Catalysts at Leerink Conference
Executives from Contineum Therapeutics (NASDAQ:CTNM) outlined the company’s clinical priorities and upcoming catalysts during a presentation at the Leerink Global Healthcare Conference, emphasizing a shift from a discovery platform to a clinical-stage company with two lead programs and multiple tria
Beat the Market the Zacks Way: Contineum Therapeutics, Suzano, PepsiCo in Focus
Contineum Therapeutics surged 27% after a Zacks Rank upgrade, spotlighting how Zacks' strategies are beating a volatile market.
Is Contineum Therapeutics, Inc. (CTNM) Stock Outpacing Its Medical Peers This Year?
Here is how Contineum Therapeutics, Inc. (CTNM) and Quest Diagnostics (DGX) have performed compared to their sector so far this year.
Contineum Therapeutics, Inc. (NASDAQ:CTNM) surges 10%; retail investors who own 51% shares profited along with institutions
Key Insights Contineum Therapeutics' significant retail investors ownership suggests that the key decisions are...